SARS-CoV-2 Variants: A Synopsis of In Vitro Efficacy Data of Convalescent Plasma, Currently Marketed Vaccines, and Monoclonal Antibodies
Open Access
- 23 June 2021
- Vol. 13 (7), 1211
- https://doi.org/10.3390/v13071211
Abstract
We summarize here in vitro evidences of efficacy for convalescent plasma, currently approved vaccines and monoclonal antibodies against SARS-CoV-2 variants of concern (VOC: B.1.1.7, B.1.351, P.1, and B.1.617.2), variants of interest (VOI: B.1.427/B.1.429, P.2, B.1.525, P.3, B.1.526, and B.1.671.1), and other strains (B.1.1.298 and B.1.258delta). While waiting from real world clinical efficacy, these data provide guidance for the treating physician.Keywords
This publication has 109 references indexed in Scilit:
- SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral Spike vaccinesPublished by Cold Spring Harbor Laboratory ,2021
- Circulating SARS-CoV-2 spike N439K variants maintain fitness while evading antibody-mediated immunityCell, 2021
- Neutralization of UK-variant VUI-202012/01 with COVAXIN vaccinated human serumPublished by Cold Spring Harbor Laboratory ,2021
- SARS-CoV-2 B.1.1.7 sensitivity to mRNA vaccine-elicited, convalescent and monoclonal antibodiesPublished by Cold Spring Harbor Laboratory ,2021
- Neutralization of N501Y mutant SARS-CoV-2 by BNT162b2 vaccine-elicited seraPublished by Research Square Platform LLC ,2021
- 2021: a new year for the WHONature Medicine, 2021
- Confirmed Reinfection With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variant VOC-202012/01Clinical Infectious Diseases, 2021
- Neutralization of N501Y mutant SARS-CoV-2 by BNT162b2 vaccine-elicited seraBiorxiv, 2021
- Viral infection neutralization tests: A focus on severe acute respiratory syndrome‐coronavirus‐2 with implications for convalescent plasma therapyReviews in Medical Virology, 2020
- Coronavirus outbreak in Nigeria: Burden and socio-medical response during the first 100 daysInternational Journal of Infectious Diseases, 2020